Lower CD226 and high TIGIT may predict poor prognosis in AML patients and the imbalance in TIGIT/CD226 axis may be the immune checkpoint barrier responsible for T-cell immune dysfunction [56]. The gene discussed is TIGIT; the disease is acute myeloid leukemia.